Real-world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register
Issued Date
2023-01-01
Resource Type
ISSN
14628902
eISSN
14631326
Scopus ID
2-s2.0-85139068768
Pubmed ID
36082513
Journal Title
Diabetes, Obesity and Metabolism
Volume
25
Issue
1
Start Page
208
End Page
221
Rights Holder(s)
SCOPUS
Bibliographic Citation
Diabetes, Obesity and Metabolism Vol.25 No.1 (2023) , 208-221
Suggested Citation
Lim L.L., Lau E.S.H., Cheung J.T.K., Chan S.P., Ji L., Lim S., Sirinvaravong S., Unnikrishnan A.G., Luk A.O.Y., Cortese V., Durocher A., Chan J.C.N. Real-world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register. Diabetes, Obesity and Metabolism Vol.25 No.1 (2023) , 208-221. 221. doi:10.1111/dom.14865 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/82341
Title
Real-world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register
Other Contributor(s)
Abstract
Aims: To explore the patterns of use of oral glucose-lowering drugs (OGLDs) in Asian patients with type 2 diabetes (T2D), focusing on sulphonylureas (SUs), and to describe patient profiles according to treatment regimen. Methods: We conducted a cross-sectional analysis of data from adults with T2D from 11 Asian countries/regions with structured assessment enrolled in the prospective Joint Asia Diabetes Evaluation (JADE) register between November 2007 and December 2019. Patients receiving insulin and/or injectable glucagon-like peptide-1 receptor agonists were excluded. Results: Amongst 62 512 patients (mean ± standard deviation age: 57.3 ± 11.8 years; 53.6% men), 54 783 (87.6%) were treated with OGLDs at enrolment. Most received one (37.5%) or two (44.2%) OGLDs. In the entire cohort, 59.4% of treated patients received SU-based therapy with variations amongst countries/regions. Overall, 79.5% of SU regimens were based on SUs plus metformin, and 22.1% on SUs plus dipeptidyl peptidase-4 inhibitors. Among SU users, gliclazide was most commonly prescribed (46.7%), followed by glimepiride (40.0%) and glibenclamide (8.1%). More gliclazide users entered the cohort with glycated haemoglobin levels <53 mmol/mol (7%) than non-gliclazide SU users (odds ratio [OR] 1.09, 95% CI 1.02-1.17), with less frequent self-reported hypoglycaemia in the 3 months before registration (OR 0.81, 95% CI 0.72-0.92; adjusted for sociodemographic factors, cardiometabolic risk factors, complications, use of other OGLDs, country/region and year of registration). Conclusion: In Asia, SUs are a popular OGLD class, often combined with metformin. Good glycaemic control and safety profiles associated with the use of SUs, including gliclazide, support their position as a key treatment option in patients with T2D.